Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis
Identifieur interne : 002F45 ( Main/Curation ); précédent : 002F44; suivant : 002F46Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis
Auteurs : Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis]Source :
- Drug safety [ 0114-5916 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adverse Drug Reaction Reporting Systems, Agonist, Antiparkinson agent, Benzothiazoles, Chemotherapy, Comparative study, Controlled therapeutic trial, D2 Dopamine receptor, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dopamine agonist, Human, Humans, Indoles (adverse effects), Indoles (therapeutic use), Metaanalysis, Neuroprotective agent, Parkinson Disease (drug therapy), Parkinson disease, Pramipexole, Randomized Controlled Trials as Topic, Review, Risk Assessment, Ropinirole, Thiazoles (adverse effects), Thiazoles (therapeutic use), Toxicity, Treatment.
- MESH :
- chemical , adverse effects : Dopamine Agonists, Indoles, Thiazoles.
- chemical , therapeutic use : Dopamine Agonists, Indoles, Thiazoles.
- chemical : Benzothiazoles.
- drug therapy : Parkinson Disease.
- Adverse Drug Reaction Reporting Systems, Humans, Randomized Controlled Trials as Topic, Risk Assessment.
Abstract
Background: Pramipexole and ropinirole are relatively new dopamine agonists, both of which have proven efficacy in the treatment of Parkinson's disease. There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug. Objective: To compare the adverse events of pramipexole and ropinirole as reported in the peer-reviewed medical literature. Methods: We systematically reviewed the medical literature to identify randomised controlled trials of pramipexole and ropinirole used in the management of Parkinson's disease. Computerised databases (including Medline, Embase, the Cochrane Library, and the International Pharmaceutical Abstracts) were used to identify pertinent articles for inclusion in this study. Trials that compared the dopamine agonists to either levodopa or placebo were included. Analysis: Adverse events with these drugs included dizziness, nausea, hypotension, hallucinations, and somnolence. We made two separate analyses. In the first analysis, we estimated the pooled relative risk (RR) of adverse events with either pramipexole or ropinirole as compared with levodopa. In the second analysis, the pooled RRs of adverse events with pramipexole and ropinirole were compared with placebo. We used the random-effects model of DerSimonian and Laird to estimate the RRs and their corresponding 95% CIs. We tested for study heterogeneity using Q statistics. Results: There was no significant difference in the risk of dizziness, nausea, or hypotension with either drug individually or in combination when compared with levodopa. The risk of hypotension was approximately four times higher with ropinirole than pramipexole when each drug was individually compared with placebo (6.46 [95% CI 1.47-28.28] for ropinirole, and 1.65 [0.88-3.08] for pramipexole). The pooled RR (for pramipexole and ropinirole combined) of hallucinations was 1.92 (95% Cl 1.08-3.43) when compared with levodopa. Relative to placebo, pramipexole had a significantly higher risk of hallucinations than ropinirole (pramipexole 5.2 [95% CI 1.97-13.721] vs ropinirole 2.75 [95%. Cl 0.55-13.73]). There was no significant difference in the risk of somnolence between the two drugs when each was individually compared with levodopa. When compared with placebo, the pooled RR (pramipexole and ropinirole combined) of somnolence was 3.16 (95% Cl 1.62-6.13). Relative to placebo, the risk of somnolence was 2.01(95% CI 2.17-3.16) with pramipexole and 5.73 (95% Cl 2.34-14.01) with ropinirole. Conclusions: Use of ropinirole seems to be associated with a higher risk of hypotension and somnolence than use of pramipexole when compared with placebo. Use of pramipexole seems to be associated with a higher risk of hallucinations than use of ropinirole when compared with placebo.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A60
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000263
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000967
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003353
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001467
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001467
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001467
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000291
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000291
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000291
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003185
Links to Exploration step
Pascal:03-0402024Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Gill, Sudeep" sort="Gill, Sudeep" uniqKey="Gill S" first="Sudeep" last="Gill">Sudeep Gill</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Neurology, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0402024</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0402024 INIST</idno>
<idno type="RBID">Pascal:03-0402024</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A60</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000263</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000967</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000967</idno>
<idno type="wicri:doubleKey">0114-5916:2003:Etminan M:comparison:of:the</idno>
<idno type="wicri:Area/Main/Merge">003353</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12688834</idno>
<idno type="wicri:Area/PubMed/Corpus">001467</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001467</idno>
<idno type="wicri:Area/PubMed/Curation">001467</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001467</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001467</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001467</idno>
<idno type="wicri:Area/Ncbi/Merge">000291</idno>
<idno type="wicri:Area/Ncbi/Curation">000291</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000291</idno>
<idno type="wicri:doubleKey">0114-5916:2003:Etminan M:comparison:of:the</idno>
<idno type="wicri:Area/Main/Merge">003185</idno>
<idno type="wicri:Area/Main/Curation">002F45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Gill, Sudeep" sort="Gill, Sudeep" uniqKey="Gill S" first="Sudeep" last="Gill">Sudeep Gill</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Neurology, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drug safety</title>
<title level="j" type="abbreviated">Drug saf.</title>
<idno type="ISSN">0114-5916</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drug safety</title>
<title level="j" type="abbreviated">Drug saf.</title>
<idno type="ISSN">0114-5916</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term>
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Benzothiazoles</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Controlled therapeutic trial</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine agonist</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (adverse effects)</term>
<term>Indoles (therapeutic use)</term>
<term>Metaanalysis</term>
<term>Neuroprotective agent</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Pramipexole</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Review</term>
<term>Risk Assessment</term>
<term>Ropinirole</term>
<term>Thiazoles (adverse effects)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Benzothiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term>
<term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Risk Assessment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pramipexole</term>
<term>Ropinirole</term>
<term>Parkinson maladie</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Stimulant dopaminergique</term>
<term>Antiparkinsonien</term>
<term>Neuroprotecteur</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Toxicité</term>
<term>Etude comparative</term>
<term>Métaanalyse</term>
<term>Article synthèse</term>
<term>Essai thérapeutique contrôlé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Pramipexole and ropinirole are relatively new dopamine agonists, both of which have proven efficacy in the treatment of Parkinson's disease. There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug. Objective: To compare the adverse events of pramipexole and ropinirole as reported in the peer-reviewed medical literature. Methods: We systematically reviewed the medical literature to identify randomised controlled trials of pramipexole and ropinirole used in the management of Parkinson's disease. Computerised databases (including Medline, Embase, the Cochrane Library, and the International Pharmaceutical Abstracts) were used to identify pertinent articles for inclusion in this study. Trials that compared the dopamine agonists to either levodopa or placebo were included. Analysis: Adverse events with these drugs included dizziness, nausea, hypotension, hallucinations, and somnolence. We made two separate analyses. In the first analysis, we estimated the pooled relative risk (RR) of adverse events with either pramipexole or ropinirole as compared with levodopa. In the second analysis, the pooled RRs of adverse events with pramipexole and ropinirole were compared with placebo. We used the random-effects model of DerSimonian and Laird to estimate the RRs and their corresponding 95% CIs. We tested for study heterogeneity using Q statistics. Results: There was no significant difference in the risk of dizziness, nausea, or hypotension with either drug individually or in combination when compared with levodopa. The risk of hypotension was approximately four times higher with ropinirole than pramipexole when each drug was individually compared with placebo (6.46 [95% CI 1.47-28.28] for ropinirole, and 1.65 [0.88-3.08] for pramipexole). The pooled RR (for pramipexole and ropinirole combined) of hallucinations was 1.92 (95% Cl 1.08-3.43) when compared with levodopa. Relative to placebo, pramipexole had a significantly higher risk of hallucinations than ropinirole (pramipexole 5.2 [95% CI 1.97-13.721] vs ropinirole 2.75 [95%. Cl 0.55-13.73]). There was no significant difference in the risk of somnolence between the two drugs when each was individually compared with levodopa. When compared with placebo, the pooled RR (pramipexole and ropinirole combined) of somnolence was 3.16 (95% Cl 1.62-6.13). Relative to placebo, the risk of somnolence was 2.01(95% CI 2.17-3.16) with pramipexole and 5.73 (95% Cl 2.34-14.01) with ropinirole. Conclusions: Use of ropinirole seems to be associated with a higher risk of hypotension and somnolence than use of pramipexole when compared with placebo. Use of pramipexole seems to be associated with a higher risk of hallucinations than use of ropinirole when compared with placebo.</div>
</front>
</TEI>
<double idat="0114-5916:2003:Etminan M:comparison:of:the"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Gill, Sudeep" sort="Gill, Sudeep" uniqKey="Gill S" first="Sudeep" last="Gill">Sudeep Gill</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Neurology, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0402024</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0402024 INIST</idno>
<idno type="RBID">Pascal:03-0402024</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A60</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000263</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000967</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000967</idno>
<idno type="wicri:doubleKey">0114-5916:2003:Etminan M:comparison:of:the</idno>
<idno type="wicri:Area/Main/Merge">003353</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Gill, Sudeep" sort="Gill, Sudeep" uniqKey="Gill S" first="Sudeep" last="Gill">Sudeep Gill</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Neurology, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drug safety</title>
<title level="j" type="abbreviated">Drug saf.</title>
<idno type="ISSN">0114-5916</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drug safety</title>
<title level="j" type="abbreviated">Drug saf.</title>
<idno type="ISSN">0114-5916</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Controlled therapeutic trial</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Human</term>
<term>Metaanalysis</term>
<term>Neuroprotective agent</term>
<term>Parkinson disease</term>
<term>Pramipexole</term>
<term>Review</term>
<term>Ropinirole</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pramipexole</term>
<term>Ropinirole</term>
<term>Parkinson maladie</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Stimulant dopaminergique</term>
<term>Antiparkinsonien</term>
<term>Neuroprotecteur</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Toxicité</term>
<term>Etude comparative</term>
<term>Métaanalyse</term>
<term>Article synthèse</term>
<term>Essai thérapeutique contrôlé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Pramipexole and ropinirole are relatively new dopamine agonists, both of which have proven efficacy in the treatment of Parkinson's disease. There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug. Objective: To compare the adverse events of pramipexole and ropinirole as reported in the peer-reviewed medical literature. Methods: We systematically reviewed the medical literature to identify randomised controlled trials of pramipexole and ropinirole used in the management of Parkinson's disease. Computerised databases (including Medline, Embase, the Cochrane Library, and the International Pharmaceutical Abstracts) were used to identify pertinent articles for inclusion in this study. Trials that compared the dopamine agonists to either levodopa or placebo were included. Analysis: Adverse events with these drugs included dizziness, nausea, hypotension, hallucinations, and somnolence. We made two separate analyses. In the first analysis, we estimated the pooled relative risk (RR) of adverse events with either pramipexole or ropinirole as compared with levodopa. In the second analysis, the pooled RRs of adverse events with pramipexole and ropinirole were compared with placebo. We used the random-effects model of DerSimonian and Laird to estimate the RRs and their corresponding 95% CIs. We tested for study heterogeneity using Q statistics. Results: There was no significant difference in the risk of dizziness, nausea, or hypotension with either drug individually or in combination when compared with levodopa. The risk of hypotension was approximately four times higher with ropinirole than pramipexole when each drug was individually compared with placebo (6.46 [95% CI 1.47-28.28] for ropinirole, and 1.65 [0.88-3.08] for pramipexole). The pooled RR (for pramipexole and ropinirole combined) of hallucinations was 1.92 (95% Cl 1.08-3.43) when compared with levodopa. Relative to placebo, pramipexole had a significantly higher risk of hallucinations than ropinirole (pramipexole 5.2 [95% CI 1.97-13.721] vs ropinirole 2.75 [95%. Cl 0.55-13.73]). There was no significant difference in the risk of somnolence between the two drugs when each was individually compared with levodopa. When compared with placebo, the pooled RR (pramipexole and ropinirole combined) of somnolence was 3.16 (95% Cl 1.62-6.13). Relative to placebo, the risk of somnolence was 2.01(95% CI 2.17-3.16) with pramipexole and 5.73 (95% Cl 2.34-14.01) with ropinirole. Conclusions: Use of ropinirole seems to be associated with a higher risk of hypotension and somnolence than use of pramipexole when compared with placebo. Use of pramipexole seems to be associated with a higher risk of hallucinations than use of ropinirole when compared with placebo.</div>
</front>
</TEI>
</INIST>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="4"><nlm:affiliation>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gill, Sudeep" sort="Gill, Sudeep" uniqKey="Gill S" first="Sudeep" last="Gill">Sudeep Gill</name>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:12688834</idno>
<idno type="pmid">12688834</idno>
<idno type="wicri:Area/PubMed/Corpus">001467</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001467</idno>
<idno type="wicri:Area/PubMed/Curation">001467</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001467</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001467</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001467</idno>
<idno type="wicri:Area/Ncbi/Merge">000291</idno>
<idno type="wicri:Area/Ncbi/Curation">000291</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000291</idno>
<idno type="wicri:doubleKey">0114-5916:2003:Etminan M:comparison:of:the</idno>
<idno type="wicri:Area/Main/Merge">003185</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.</title>
<author><name sortKey="Etminan, Mahyar" sort="Etminan, Mahyar" uniqKey="Etminan M" first="Mahyar" last="Etminan">Mahyar Etminan</name>
<affiliation wicri:level="4"><nlm:affiliation>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Kunin-Lunenfeld Applied Research Unit, Department of Clinical Epidemiology, Baycrest Center for Geriatric Care, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gill, Sudeep" sort="Gill, Sudeep" uniqKey="Gill S" first="Sudeep" last="Gill">Sudeep Gill</name>
</author>
<author><name sortKey="Samii, Ali" sort="Samii, Ali" uniqKey="Samii A" first="Ali" last="Samii">Ali Samii</name>
</author>
</analytic>
<series><title level="j">Drug safety</title>
<idno type="ISSN">0114-5916</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term>
<term>Benzothiazoles</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Humans</term>
<term>Indoles (adverse effects)</term>
<term>Indoles (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Risk Assessment</term>
<term>Thiazoles (adverse effects)</term>
<term>Thiazoles (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Benzothiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term>
<term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Risk Assessment</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pramipexole and ropinirole are relatively new dopamine agonists, both of which have proven efficacy in the treatment of Parkinson's disease. There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002F45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Curation |type= RBID |clé= Pascal:03-0402024 |texte= Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |